Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

卡铂 医学 肿瘤科 内科学 卵巢癌 化疗 癌症 紫杉醇 顺铂
作者
Claire Falandry,Frédérique Rousseau,Marie‐Ange Mouret‐Reynier,Fabien Tinquaut,Domenica Lorusso,Jørn Herrstedt,Aude-Marie Savoye,Laëtitia Stefani,Emmanuelle Bourbouloux,Robert Sverdlin,Véronique D’Hondt,Alain H. Lortholary,Pierre-Emmanuel Brachet,Alain Zannetti,Emmanuelle Malaurie,Laurence Venat‐Bouvet,Olivier Trédan,Loïc Mourey,Éric Pujade-Lauraine,Gilles Freyer
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (6): 853-853 被引量:82
标识
DOI:10.1001/jamaoncol.2021.0696
摘要

IMPORTANCE: Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have a detrimental effect on outcomes for these patients. OBJECTIVE: To compare the feasibility, efficacy, and safety of single-agent carboplatin every 3 weeks, weekly carboplatin-paclitaxel, or conventional every-3-weeks carboplatin-paclitaxel in vulnerable older patients with ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: This international, open-label, 3-arm randomized clinical trial screened 447 women 70 years and older with newly diagnosed stage III/IV ovarian cancer by determining their Geriatric Vulnerability Score; 120 patients with a Geriatric Vulnerability Score of 3 or higher were stratified by country and surgical outcome. Enrollment took place at 48 academic centers in France, Italy, Finland, Denmark, Sweden, and Canada from December 11, 2013, to April 26, 2017. Final analysis database lock April 2019. Data analysis was performed from February 1 to December 31, 2019. INTERVENTIONS: Patients were randomized to receive 6 cycles of (1) carboplatin, area under the curve (AUC) 5 mg/mL·min, plus paclitaxel, 175 mg/m2, every 3 weeks; (2) single-agent carboplatin, AUC 5 mg/mL·min or AUC 6 mg/mL·min, every 3 weeks; or (3) weekly carboplatin, AUC 2 mg/mL·min, plus paclitaxel, 60 mg/m2, on days 1, 8, and 15 every 4 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was treatment feasibility, defined as the ability to complete 6 chemotherapy cycles without disease progression, premature toxic effects-related treatment discontinuation, or death. RESULTS: A total of 120 women were randomized. The mean and median age was 80 (interquartile range, 76-83; range, 70-94) years; 43 (36%) had a Geriatric Vulnerability Score of 4 and 13 (11%) had a Geriatric Vulnerability Score of 5; 40 (33%) had stage IV disease. During its third meeting, the independent data monitoring committee's recommendation led to the termination of the trial because single-agent carboplatin was associated with significantly worse survival. Six cycles were completed in 26 of 40 (65%), 19 of 40 (48%), and 24 of 40 (60%) patients in the every-3-weeks combination, single-agent carboplatin, and weekly combination groups, respectively. Treatment-related adverse events were less common with the standard every-3-weeks combination (17 of 40 [43%]) than single-agent carboplatin or weekly combination therapy (both 23 of 40 [58%]). Treatment-related deaths occurred in 4 patients (2 of 40 [5%] in each combination group). CONCLUSIONS AND RELEVANCE: This randomized clinical trial shows that compared with every-3-weeks or weekly carboplatin-paclitaxel regimens, single-agent carboplatin was less active with significantly worse survival outcomes in vulnerable older patients with ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02001272.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wzz完成签到,获得积分10
1秒前
bw完成签到,获得积分10
2秒前
执着谷兰发布了新的文献求助10
2秒前
Lucas完成签到 ,获得积分10
2秒前
2秒前
桐桐的应助被烙饼采纳,获得30
2秒前
枫荧尽染完成签到,获得积分10
2秒前
RuiLi完成签到,获得积分10
4秒前
Zhhh完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
5秒前
6秒前
7秒前
7秒前
Juvenilesy的应助被银烨采纳,获得10
7秒前
深情安青的应助被机灵的妙菡采纳,获得10
7秒前
可爱的函函的应助被六六采纳,获得10
7秒前
汉堡包的应助被机灵的妙菡采纳,获得10
9秒前
9秒前
爆米花的应助被Yolo采纳,获得10
9秒前
binges on choco完成签到,获得积分10
10秒前
啵啵发布了新的文献求助10
10秒前
10秒前
10秒前
啦啦啦发布了新的文献求助10
10秒前
10秒前
11秒前
JB发布了新的文献求助30
11秒前
melon完成签到,获得积分10
11秒前
哈哈哈发布了新的文献求助10
11秒前
斯文败类的应助被机灵的妙菡采纳,获得10
11秒前
33完成签到 ,获得积分10
12秒前
Gaara0504完成签到,获得积分10
12秒前
顾勇完成签到,获得积分0
12秒前
耶耶耶发布了新的文献求助10
12秒前
科研通AI6.4的应助被xiaolizi采纳,获得10
13秒前
13秒前
唐Doctor完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496